Biofrontera (BFRI) Stock Price, News & Analysis

Company Overview

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key Stats

• Today's Range: $0.92 to $1.06
• 50-Day Range: $0.60 to $1.11
• 52-Week Range: $0.54 to $2.22
• Volume: 35,774 shs
• Average Volume: 85,050 shs
• Market Capitalization: $9.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.75
• Consensus Rating: Buy

Biofrontera Stock Analysis - MarketRank™

Biofrontera scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biofrontera has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biofrontera are expected to grow in the coming year, from ($3.01) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biofrontera is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biofrontera is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biofrontera has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.14% of the float of Biofrontera has been sold short.

Short Interest Ratio / Days to Cover

Biofrontera has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biofrontera has recently decreased by 17.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biofrontera does not currently pay a dividend.

Dividend Growth

Biofrontera does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.14% of the float of Biofrontera has been sold short.

Short Interest Ratio / Days to Cover

Biofrontera has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biofrontera has recently decreased by 17.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.31

News Sentiment

Biofrontera has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Biofrontera this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for BFRI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biofrontera insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Biofrontera is held by insiders.

Percentage Held by Institutions

Only 10.08% of the stock of Biofrontera is held by institutions.

BFRI Stock Analysis - Frequently Asked Questions

How have BFRI shares performed this year?

Biofrontera's stock was trading at $1.09 on January 1st, 2025. Since then, BFRI stock has decreased by 11.4% and is now trading at $0.9660.

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.12. The business had revenue of $9.03 million for the quarter, compared to analyst estimates of $8.30 million. Biofrontera had a negative trailing twelve-month return on equity of 457.54% and a negative net margin of 42.34%.
Read the conference call transcript.

When did Biofrontera's stock split?

Biofrontera shares reverse split before market open on Wednesday, July 5th 2023.The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Biofrontera IPO?

Biofrontera (BFRI) raised $19 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO.

Who are Biofrontera's major shareholders?

Top institutional shareholders of Biofrontera include AIGH Capital Management LLC (9.61%).

How do I buy shares of Biofrontera?

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biofrontera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NVIDIA (NVDA), NIO (NIO) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BFRI
• CIK: 1858685
• Web: www.biofrontera-us.com
• Phone: 781-245-1325
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biofrontera: $2.75
• High Price Target: $2.75
• Low Price Target: $2.75
• Potential Upside/Downside: +184.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.76 million
• Net Margins: -42.34%
• Pretax Margin: -30.28%
• Return on Equity: -457.54%
• Return on Assets: -83.44%

Debt

• Debt-to-Equity Ratio: 8.99
• Current Ratio: 1.40
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: $37.32 million
• Price / Sales: 0.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 10,140,000
• Free Float: 9,652,000
• Market Cap: $9.80 million
• Optionable: No Data
• Beta: 0.50